FREDUN · NSE
Fredun Pharmaceuticals Limited
₹1,303.5
+1.98% (+₹25.3)
Prev. close
₹1,278.2
Volume
65,181
Delivery %
51.6%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Fredun Pharmaceuticals Limited
Fredun Pharmaceuticals Limited manufactures and sells pharmaceutical formulations, dietary/herbal supplements, nutraceuticals, animal healthcare products, cosmeceuticals, mobility and rehabilitation products, and other healthcare products in India, Africa, Southeast Asia, Commonwealth of Independent States countries, MENA region, and Latin America. The company offers allopathic formulations, including analgesics/NSAID, antacid/antiulcer, anthelmintic, antibacterial, anti-diabetic, anti-inflammatory, anti-malarial, anti-obesity, antacid, anthelmintic, anticoagulants, anticonvulsants, antidiarrhoeal, antidepressant, antifungal, antihistamines/antiallergic, antihypertensives, antiviral, bone modulating drugs, bronchodilators and anti-asthma drugs, calcium tablets, cardiovascular, diuretic, impotence drugs, laxative, and appetite stimulant with multivitamins. It also provides surgical products, such as IV fluids and cannulas, disposable syringes, infusion sets, surgical gloves and cottons, and personal healthcare products; APIs; direct compressible granules; pellets; animal healthcare products; aqua products; and niche products. Additionally, the company offers therapeutic products under the brand Hormone Range Products, a specialty therapeutics brand focused on longevity, hormone health, recovery science, and human performance solutions. Fredun Pharmaceuticals Limited was incorporated in 1987 and is headquartered in Mumbai, India.,
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Daulat Nariman Medhora
Headquarters
Mumbai
Employees
736
Website
fredungroup.comExchange
View on NSE ↗Key stats
Market cap
₹2,191.09 Cr
P/E ratio (TTM)
56.6
Dividend yield
0.05%
EPS (TTM)
₹23.01
Beta (5Y monthly)
0.76
Shares float
1.00 Cr
EPS · quarter ended Jun 2026
₹7.40
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY22 growth needs FY21 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹131.55 Cr | ₹221.74 Cr | ₹274.34 Cr | ₹346.58 Cr | ₹451.71 Cr | ₹633.33 Cr | |
| EBITDA | ₹10.54 Cr | ₹15.43 Cr | ₹27.88 Cr | ₹37.77 Cr | ₹52.96 Cr | ₹92.73 Cr |
| ₹2.02 Cr | ₹6.34 Cr | ₹10.81 Cr | ₹15.62 Cr | ₹19.74 Cr | ₹32.62 Cr | |
| Diluted EPS | — | — | ₹7.64 | ₹11.11 | ₹0 | ₹0 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹161.62 Cr | ₹186.99 Cr | ₹257.28 Cr | ₹307.60 Cr | ₹487.41 Cr | ₹642.08 Cr | |
| ₹39.64 Cr | ₹52.76 Cr | ₹86.55 Cr | ₹105.51 Cr | ₹168.38 Cr | ₹242.27 Cr | |
| Stockholders' equity | ₹43.07 Cr | ₹68.06 Cr | ₹96.38 Cr | ₹121.47 Cr | ₹141.38 Cr | ₹281.62 Cr |
Fixed assets, Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹-14.41 Cr | ₹-43.87 L | ₹-16.60 Cr | ₹11.90 Cr | |
| Investing cash flow | — | — | ₹-9.40 Cr | ₹-7.64 Cr | ₹-6.35 Cr | ₹-73.59 Cr |
| Financing cash flow | — | — | ₹25.18 Cr | ₹5.99 Cr | ₹26.65 Cr | ₹121.45 Cr |
| Capital expenditure | — | — | ₹-9.49 Cr | ₹-7.64 Cr | ₹-6.11 Cr | ₹-73.59 Cr |
| End cash position | — | — | ₹3.44 Cr | ₹1.35 Cr | ₹5.22 Cr | ₹64.98 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Fredun Pharmaceuticals Limited | ₹2,148.56 Cr | ₹1,303.5 | 55.4 | 7.63 | 11.6% | 0.86 | +40.2% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 26
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Fredun Pharmaceuticals Ltd. Acquires Furlicks from Pharma Major USV & its subsidiary Wellbeing Nutrition
The Tribune · 3 days ago
Furlicks Goes from 6 to 22 SKUs: Fredun Pharmaceuticals Ltd. Accelerates Pet Wellness Expansion
Fredun Pharmaceuticals Ltd. is expanding its pet wellness brand, Furlicks, from 6 to 22 product SKUs over the next 6-9 months. This expansion will introduce 16 new products beyond oral strips, including dissolving strips and functional biscuits. The move aims to broaden Furlicks' reach in the pet care market and leverage FPL's manufacturing and R&D capabilities.